Entity
Medication Affordability and Patent Integrity Act (S. 2658)
S. 2658, the Medication Affordability and Patent Integrity Act, would make prescription drug patents unenforceable over paperwork errors, a measure its supporters say will lower drug prices but which critics argue threatens legitimate pharmaceutical patents. The bill was reported by the Senate HELP Committee in July 2026 and remains under congressional consideration.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Overview
The Medication Affordability and Patent Integrity Act (S. 2658) is a bill pending in the U.S. Congress that would allow patents on prescription drugs to be rendered unenforceable in cases of paperwork errors, even where the underlying invention is novel and non-obvious (IPWatchdog, October 21). The Senate Health, Education, Labor, and Pensions (HELP) Committee reported the bill in July (IPWatchdog, October 21).
## Purpose and Debate
Supporters argue the bill will lower drug prices by closing a loophole that drugmakers allegedly use to extend patent monopolies (IPWatchdog, October 21). Critics, including the IPWatchdog commentary, contend the bill risks invalidating valuable medicine patents over "honest paperwork error[s]" unrelated to the merits of the invention (IPWatchdog, October 21).
## Strategic Importance
This bill is significant for pharmaceutical patent strategy and enforcement. If enacted, it could materially change risk calculus for drug patent prosecution and litigation, affecting innovator pharmaceutical companies, generic manufacturers, and patent counsel. Given ongoing congressional attention to drug pricing, this is likely to remain a developing legislative story.